Delays in drug manufacturing can disrupt timelines and increase costs, but the right partnership strategies help keep projects on schedule.
Pharmaceutical and biotech companies rely on contract development and manufacturing organizations (CDMOs) to bring products to market efficiently.
While outsourcing to a CDMO can accelerate development timelines and reduce upfront investment, it also introduces risks if not managed properly. One of the biggest concerns is project delays, which can translate into missed clinical milestones, budget overruns, and lost market opportunities.
To avoid such setbacks, companies must take a proactive, partnership-driven approach with their CDMO. Below are seven expert-recommended strategies to help prevent delays in CDMO manufacturing projects.
1. Select a CDMO with the Right Expertise and Capacity
Choosing the right CDMO manufacturing partner from the start is critical. Before signing a contract, perform thorough due diligence on the CDMO’s capabilities and track record.
Ensure they have experience with your product type, relevant process knowledge, and a history of meeting project timelines.
The CDMO should be able to handle your project’s current needs and ramp up for larger volumes if the program advances. Otherwise, capacity shortfalls could lead to delays down the road.
2. Define a Clear Project Scope, Timeline, and Goals
At project kickoff, invest time in jointly developing a detailed scope of work with the CDMO.
The contract or technical agreement should precisely outline the services, timelines, and requirements of each party. Key elements to define include:
- Deliverables and tasks: List all development work, analytical tests, validation runs, production batches, etc. that the CDMO will execute
- Milestones and timeline: Set target dates for each phase, such as tech transfer completion, pilot batch, GMP manufacturing, and quality release
- Success criteria: Agree on metrics like yield, purity, or other quality attributes that define acceptable output
- Documentation and reporting: Clarify what data/reports will be provided and when, such as batch records, development reports, deviation reports, etc.
By documenting these details upfront (and updating them as needed), both the company and CDMO have a shared blueprint for execution. Without a clear scope and defined goals, even small misunderstandings can balloon into missed CDMO manufacturing timelines and budget overruns.
3. Execute a Thorough Technology Transfer
To prevent hiccups, approach tech transfer in a structured, collaborative manner. Discuss the CDMO manufacturing process with detailed documentation, standard operating procedures (SOPs), and analytical methods.
It’s often wise to perform small-scale feasibility or engineering batches before committing to full GMP production. This way, any unforeseen technical issues can be identified and resolved early.
As close coordination is key, assign dedicated point-of-contact personnel on both sides to manage the data exchange and troubleshooting during transfer. When technology transfer is properly executed, it saves time and money by smoothing out issues before they become major roadblocks at scale.
4. Ensure Quality and Regulatory Compliance
A batch might need to be remade, or regulatory filings could be rejected if proper procedures weren’t followed.
Therefore, establish early on that the CDMO manufacturing is entirely cGMP compliant with applicable authorities and be willing to review their quality history.
Ensure the CDMO has a quality-focused culture with change controls, deviation management, and regular audits to catch and fix issues proactively.
Remember that maintaining high quality helps avoid penalties and ensures customer satisfaction. It’s fundamental to avoiding rework and supply interruptions. Both the client and the CDMO should stay updated on evolving regulations and plan for new requirements, like data integrity or validation updates, to avoid surprises.
5. Plan Capacity and Supply Chain with Buffers
Ask for a resource and production forecast to understand the CDMO’s manufacturing schedule.
If the CDMO is juggling many projects, you may need to reserve production campaigns well in advance or negotiate dedicated capacity.
It’s also prudent to build buffer time into the schedule. For instance, plan to have clinical trial materials ready a few weeks before they are absolutely needed, to cushion against any unexpected hiccups.
Another potential cause of delays is raw material or component shortages. Discuss the bill of materials with the CDMO and identify any long-lead or single-source raw materials. Ensuring those critical inputs are secured ahead of time (or having backup suppliers) can prevent last-minute holdups.
6. Implement Change Control and Risk Mitigation Plans
Uncontrolled changes can wreak havoc on timelines and budgets. To avoid chaos, establish a formal change control process with your CDMO.
This means any proposed change in scope, process parameters, batch size, specifications, or timelines should trigger an evaluation of the impact on schedule and cost. Alongside change control, it’s wise to maintain a contingency reserve in both timeline and budget.
For example, adding a few extra weeks of buffer in the project schedule for high-risk steps, and setting aside roughly 10–15% of the budget for unplanned activities, can cover minor setbacks without derailing the whole project.
Risk management should be an ongoing part of CDMO manufacturing as well. In joint meetings, periodically review potential risks (technical, logistical, or regulatory) and ensure there are mitigation plans for each. Perhaps a critical piece of equipment could fail. Does the CDMO have redundant capacity or a workaround? Or if initial batches underperform, is there time in the schedule for process optimization or an extra batch?
By anticipating scenarios and agreeing on backup plans, the team can respond quickly rather than being caught off guard.
7. Maintain Transparent and Frequent Communication
Effective communication is the glue that holds all the above strategies together. A CDMO manufacturing process must be managed actively, by establishing clear communication channels and cadence at the outset of the project:
- Regular status updates: Schedule weekly or biweekly project calls to review progress, next steps, and any blockers. Consistent touchpoints help catch potential delays early
- Governance meetings: Hold a high-level review (e.g. monthly) with project leaders and stakeholders from both companies to discuss overall timeline, resources, and any critical decisions
- Issue escalation protocol: Agree on how urgent issues will be communicated (for example, an immediate phone call for critical deviations or test failures) and who the point persons are to resolve them
- Shared data access: Utilize project management software or a shared document portal so that both teams can monitor task status, review data, and stay aligned in real time.
By fostering an open, two-way communication culture, trust is built, and both the client and the CDMO can jointly navigate challenges.
Partnering for On-Time Success in CDMO Manufacturing
Delays in CDMO manufacturing projects are not inevitable. With the right partner and a proactive, collaborative approach, most pitfalls can be anticipated and prevented.
The strategies outlined above center on building a strong partnership focused on common goals. Therefore, by investing in proper project management, companies can significantly accelerate the development of lifesaving therapies to market.
Neuland Labs exemplifies these best practices in action. As a global CDMO specializing in small molecule and peptide APIs, Neuland brings 4 decades of experience working closely with innovators to ensure regulatory compliance and on-time delivery.
For sponsors seeking high-quality CDMO manufacturing support, partnering with an organization like Neuland Labs can provide the reliability and expertise needed to keep projects on schedule and achieve successful outcomes.
FAQs
- What red flags should I watch for before signing a CDMO manufacturing contract?
Inconsistent timelines, limited transparency, lack of regulatory history, or hesitation to share audit records are strong indicators that the CDMO may not deliver reliably. - Can delays in CDMO manufacturing affect regulatory submissions?
Yes, delays in GMP batches or inconsistent documentation can directly push back submission timelines, impacting approval windows and market entry. - How do global supply chain disruptions impact CDMO manufacturing projects?
Material shortages, shipping delays, and customs issues can all create bottlenecks. Working with a CDMO that has alternate sourcing strategies helps reduce this risk. - Is it better to use multiple CDMO manufacturing partners?
While multiple partners offer flexibility, consolidating with a proven CDMO often leads to fewer handoffs, tighter control, and more consistent timelines.
